Bicara Therapeutics

Bicara Therapeutics

Bicara Therapeutics launched in 2018, co-founded by Biocon executive Kiran Mazumdar-Shaw and a team of immuno-oncology researchers, with Rachel Salius assuming the CEO role in 2021 (per Fierce Biotech, 2021). The firm operates as a clinical-stage biotechnology company, not a traditional family office or allocator — its capital is venture-funded, and its structure is designed to advance a novel bifunctional antibody platform through Phase 2/3 trials. Biocon remains a strategic backer, providing both financial and manufacturing support, while a syndicate of life sciences investors including Red Tree Venture Capital and others have participated in its funding rounds. The firm's strategy concentrates exclusively on developing ficerafusp alfa (BCA101), a first-in-class bifunctional fusion protein that simultaneously inhibits EGFR and sequesters TGF-beta within the tumor microenvironment. Clinical trials target recurrent/metastatic head and neck squamous cell carcinoma, with Phase 2 dose-expansion data expected to inform a potential registrational path. Bicara does not operate a diversified pipeline; the model hinges on demonstrating statistically significant overall response rates in a well-defined patient population, then partnering or commercializing. The geographic scope is US-centric for clinical operations, with Biocon's Bangalore infrastructure providing manufacturing and early-stage development support. Bicara has raised over $150 million in disclosed venture financing, most recently closing an oversubscribed Series C in 2023 (per Endpoints News, March 2023). The firm operates from Cambridge, Massachusetts, with a lean team focused on clinical operations, regulatory strategy, and biostatistics rather than large in-house discovery. Its board includes investors from RA Capital Management and Biocon. March 2023: Closed a $108 million Series C financing to fund the ongoing Phase 2 trial of ficerafusp alfa in head and neck cancer (per Endpoints News, March 2023). Bicara's structural distinction lies in its India-to-US clinical execution axis. Unlike most US biotechs that outsource manufacturing contractually, Bicara leverages Biocon's large-scale biologics manufacturing capability as both an equity backer and a production partner — creating a hybrid cost structure that reduces burn rate during clinical development. This is not a fund, not a family office, and not a platform company: it is a single-candidate bet with an industrial partner deeply embedded in its capitalization and supply chain.